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Abstract
S-palmitoylation is a reversible post-translational modification important for controlling the membrane targeting and
function of numerous membrane proteins with diverse roles in signalling, scaffolding, and trafficking. We sought to identify
novel palmitoylated proteins in B lymphocytes using acyl-biotin exchange chemistry, coupled with differential analysis by
liquid-chromatography tandem mass spectrometry. In total, we identified 57 novel palmitoylated protein candidates from
human EBV-transformed lymphoid cells. Two of them, namely CD20 and CD23 (low affinity immunoglobulin epsilon Fc
receptor), are immune regulators that are effective/potential therapeutic targets for haematological malignancies,
autoimmune diseases and allergic disorders. Palmitoylation of CD20 and CD23 was confirmed by heterologous expression
of alanine mutants coupled with bioorthogonal metabolic labeling. This study demonstrates a new subset of palmitoylated
proteins in B cells, illustrating the ubiquitous role of protein palmitoylation in immune regulation.
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Introduction
Protein S-acylation (or S-palmitoylation, hereafter referred to as
palmitoylation) is a common post-translational modification
covalently linking long-chain fatty acids (especially 16-carbon
palmitic acid) to cysteine thiols in proteins via a labile thioester
bond, which can be highly dynamic [1]. Protein acyltransferases
and protein acylthioesterases regulate enzymatic cycling of
palmitoylation of many proteins [2,3], providing a distinct
pathway for precise regulation of membrane association. Palmi-
toylation facilitates membrane association of numerous soluble
proteins, yet many palmitoylated proteins like ion channels, cell
adhesion molecules, G-protein coupled receptors, and immune
receptors are integral membrane proteins. For these transmem-
brane proteins, palmitoylation may act as more than a simple
membrane tether. Indeed, palmitoylation has been shown to
spatiotemporally regulate many cellular processes, including
targeting to specific subcellular compartments or membrane
subdomains, trafficking, protein-protein interactions, protein
function and protein stability (reviewed in [2,4–6]). For many
proteins, palmitoylation mediates lipid raft association [7], which
describes membrane microdomains enriched in cholesterol,
glycosphingolipids and signaling proteins [8]. Recently, Freeman
and coworkers [9] provided proteomic evidence suggesting lipid
rafts and tetraspanin-rich microdomains are enriched in specific
palmitoylated proteins.
The recent development of palmitoyl-protein enrichment
methods has significantly advanced the study of palmitoylated
proteins. Acyl-biotin exchange (ABE) [10] is based on hydroxyl-
amine selective cleavage of thioester bonds, followed by free thiol
capture via a biotinylated thiol reagent. Biotinylated proteins are
then purified by affinity on immobilized streptavidin. Using this
approach, Roth et al. identified and validated 35 proteins out of 58
novel candidate yeast palmitoylated proteins [11]. Kang et al.
extended this method to study whole rat brain, embryonic rat
neurons or rat synaptosomes, confirming 21 novel palmitoylated
proteins out of .200 candidates [12]. Others have recently
reported similar studies in african trypanosomes [13], human
platelets [14], and macrophages [15]. This approach was recently
optimized to eliminate several manipulations by capturing
hydroxylamine-sensitive cysteines using a thiol-reactive resin [16].
A second method utilizes the metabolic incorporation of a
bioorthogonal palmitate analog into endogenous sites of palmi-
toylation, which may be subsequently conjugated in vitro with a tag
such as biotin [17–20]. Recently, we used this technique to purify
palmitoylated proteins from Jurkat T cells, identifying 125 high
confidence and about 200 medium confidence potentially
palmitoylated proteins [19]. Other studies by Hang’s group used
a similar approach to identify palmitoylated proteins in dendritic
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37187cells, identifying IFITM3 as an important palmitoylated protein
involved in viral infection [21].
Given the diversity of palmitoylated proteins identified in each
of these experiments, and the growing understanding of protein
palmitoylation in immune regulation, we sought to identify novel
palmitoylated proteins in B lymphocytes. Palmitoylated proteins
from immortalized B lymphoid cells were enriched using ABE
chemistry, and samples prepared with or without hydroxylamine
treatment were compared by a semi-quantitative differential
proteomic analysis based on spectral counting [22]. This analysis
method sums the number of tandem mass (MS2) spectra for a
protein, which has been demonstrated to be correlated with the
relative protein abundance, and is widely accepted for the relative
quantification of proteins between samples [23–25]. This strategy
led to the identification of 53 previously confirmed palmitoylated
proteins and 95 candidate palmitoylated proteins, including
numerous major histocompatibility complex (MHC) proteins.
Among these candidates, we focused on the B-lymphocyte antigen
CD20 and the low affinity immunoglobulin epsilon Fc receptor
(CD23). These two surface proteins are important immune
regulators with effective and/or potential therapeutic benefits
when used as markers to deplete B lymphocytes in B cell
lymphoproliferative disorders, such as follicular lymphoma or
chronic lymphocytic leukemia, autoimmune diseases such as
rheumatoid arthritis, or allergic disorders such as allergic asthma
[26–29]. This study validates CD20 and CD23 as novel, B cell
palmitoylated proteins.
Results
In order to identify potentially novel palmitoylated proteins
from human B lymphoid cells, ABE experiments were performed
following the protocol described by Drisdel and Green [10].
Thioester-containing proteins were distinguished from non-specif-
ically enriched proteins by comparing samples treated in parallel
with (HA+) or without (HA2) hydroxylamine (Figure 1). Three
independent pairs of samples were prepared and analyzed by mass
spectrometry. Results from all samples were merged, and this led
to the identification of 493 non-redundant proteins identified by at
least 2 unique peptides, 452 of which were present in the specific
HA+ sample (Figure 2A and Table S1). Fifty-nine of the identified
proteins were isoforms of MHC class I or class II proteins, which
have in some cases been described as palmitoylated [30]. Fifty-
three previously confirmed palmitoylated proteins were identified
(Table S1), including the transferrin receptor, the cation-depen-
dent mannose-6-phosphate receptor, flotillins 1 and 2, vesicular
trafficking proteins (syntaxins 6, 7, 8 and 12, SNAP23),
heterotrimeric G protein alpha subunits, and several members of
the small GTPases ras family. All proteins present in the HA+
samples were plotted by their averaged normalized spectral count
in HA+ (x-axis) and HA2 (y-axis) samples (Figure 2B). As
expected, most of the known palmitoylated proteins clustered
along the x-axis (grey squares), as did the proteins later identified
as palmitoylated candidates (see below; black circles).
Identification of potentially novel palmitoylated proteins
Putative palmitoylated proteins were partitioned into two
groups: proteins exclusively identified in specific (HA+) samples,
and proteins common to both control (HA2) and HA+ samples.
Data from the first group were filtered to proteins with at least 5
spectral counts, which led to the identification of 57 proteins. This
group includes 16 known palmitoylated proteins, 30 proteins
annotated as candidates in previous proteomic studies [9,12,14–
16,19,21,31] and 11 novel potential palmitoylated proteins (Tables
S2 and S3). In the second group (353 proteins), candidates were
searched by a spectral-count based analysis of their specific
enrichment in HA+ samples [22,24]. This enrichment, indicative
of potential palmitoylation, was evaluated using a spectral index
(SpI) that takes into account both the relative protein abundance
(assessed by normalized spectral counts) and the number of
replicates in which the protein has been found [32] (Table S3). As
depicted in Figure 3, the SpI distribution of the proteins was
clearly bimodal. Statistical analysis showed that proteins displaying
a SpI higher than 0.54, representing most proteins from the right
peak, were significantly enriched (p,0.05) in the HA+ sample over
the HA2 sample, and consequently annotated as putative
thioester-containing proteins. As expected, the SpI distribution
of previously confirmed palmitoylated proteins (Table S3 and
Figure 3, black bars) demonstrated a strong tendency to score high
SpIs (close to +1). Twenty-eight out of the 32 known palmitoylated
proteins identified in both HA2 and HA+ in this study displayed a
SpI higher than 0.54, and 18 of them had an SpI higher than 0.73
(1% significance level threshold value), illustrating the effective
enrichment of palmitoylated proteins in the HA+ samples. Using
this approach, 54 additional candidate palmitoylated proteins,
comprising 44 MHC proteins, 8 proteins identified in previous
proteomic studies [9,12,14–16,19,21,31] and 2 novel candidates,
were annotated (Tables S2 and S3). Among these candidates, the
protein that displays the lower spectral count is the B-lymphocyte
antigen CD20, with 38 spectra identified in HA+ and one in
HA2.
Figure 1. Palmitoylated proteins from human B lymphoid cells
are enriched following ABE purification. Proteins from B lymphoid
cells membranes were subjected to ABE purification with (HA+)o r
without (HA2) hydroxylamine treatment, resolved by SDS-PAGE on a 4–
12% gradient gel, and detected by silver nitrate staining.
doi:10.1371/journal.pone.0037187.g001
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of which 46 are MHC molecules and 38 have been annotated as
candidates in previous palmitoyl-proteome studies [9,12,14–
16,19,21,31] (Tables S2 and S3). The remaining 11 proteins are
completely novel candidates. All proteins meeting our criteria for
being considered as potentially palmitoylated, except for MHC
molecules, were classified by biological process, as provided by the
Human Protein Reference Database [33]. Diverse processes
throughout the cell are represented, including cellular signaling
(36.6%), vesicle fusion and membrane trafficking (14%), and
immune response (6.5%; Figure 4). Among the novel candidates,
three are annotated as implicated in signal transduction (the
interferon induced transmembrane protein 1 IFITM1, the tumor
necrosis factor receptor superfamily member 8 TNFRSF8 or
CD30, and the B-lymphocyte antigen CD20) and two in the
immune response (CD74 and the low affinity immunoglobulin
epsilon Fc receptor FCER2 or CD23).
The B lymphocyte specific immune regulators CD20 and
CD23 are novel palmitoylated candidates
The main goal of this study was to identify B cell novel
palmitoylated proteins. Among the proteins specifically enriched
in the HA+ samples, we focused on two immune regulators, CD20
and CD23. CD20 was identified by 5 peptides (39 MS2 spectra),
corresponding to 4 different sequences covering 11.3% of the
protein sequence (Table 1). CD20 was exclusively found in the
HA+ sample in two out of three experiments, displaying a SpI of
0.88 that was included in the 1% confidence interval. Similarly,
CD23 was exclusively identified in the HA+ samples for the three
replicates, by a total of 10 peptides (43 MS2 spectra), correspond-
ing to 8 unique sequences covering 32.3% of the protein sequence
(Table 1).
Validation of CD20 and CD23 as novel palmitoylated
proteins
CD20 is a non-glycosylated four-pass transmembrane protein
with a large extracellular loop located between the third and
fourth transmembrane segments [34] (Figure 5). Two out of five
cysteines are located on the extracellular loop, excluding them as
potential palmitoylation sites. The three intracellular cysteines
(Cys
81, Cys
111 and Cys
220) are candidate sites of CD20
palmitoylation. Cys
81 is predicted to be embedded within the first
Figure 2. Graphical analysis of the B cell palmitoyl-proteome.
(A) Overlap between proteins identified in the HA2 or HA+ samples.
Results from the triplicate analyses were merged and led to a list of 493
proteins that distribute as depicted in the Venn diagram. The numbers
of proteins identified exclusively in the HA2 samples, common to HA2
and HA+ samples or exclusively identified in the HA+ samples are
indicated. (B) Proteins identified in the HA+ samples (452 proteins) were
plotted by their averaged normalized spectral counts in the HA+ (x axis)
and the HA2 (y axis) samples. The inset shows an expanded view of the
lower values zone. Novel candidate palmitoylated proteins (N) cluster
along the x-axis, as do established palmitoylated proteins (m) and many
candidate palmitoylated proteins identified in previous proteomic
studies (&). #, proteins that were not significantly enriched, according
to our statistical analysis;N, CD20 and CD23.
doi:10.1371/journal.pone.0037187.g002
Figure 3. Spectral index distribution of the identified proteins.
The distribution of the SpI of the 353 proteins identified in both HA2
and HA+ samples is represented as an histogram (medium grey). The
random distribution of the SpIs was calculated according to Fu et al.
[32], in order to determine the SpI thresholds corresponding to the 5%
and 1% confidence intervals (respectively 0.54 and 0.74), and is shown
in the background (light grey). The distribution of the known
palmitoylated proteins identified in this study is superimposed in black.
doi:10.1371/journal.pone.0037187.g003
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111 reside between the
second and the third transmembrane domains in the cytoplasmic
loop and Cys
220 is in the C-terminal intracellular tail [35].
CD23 is a single-pass type II integral membrane protein
(Figure 5) which is present as a homotrimer in the cell membrane
[36]. The short N-terminal cytoplasmic tail contains two cysteines
(Cys
17 and Cys
18), which are likely sites of palmitoylation. These
cysteines are juxtaposed to the predicted cytoplasmic/transmem-
brane domain boundary and surrounded by clusters of hydro-
phobic and positively charged amino-acids, characteristics that are
often found in transmembrane palmitoylated proteins [37].
In order to validate the palmitoylation of CD20 and CD23, we
developed a heterologous expression system, where palmitoylation
of these specific candidates was assessed by transient transfection
of plasmids encoding CD20 and CD23 tagged with a C-terminal
(His)6 epitope. Additionally, in order to identify the palmitoylated
cysteines in CD20 and CD23, we generated single point mutations
in CD20 (C81A, C111A, C220A) and CD23 (C17A and C18A).
As aberrant palmitoylation frequently occurs after mutating a
cysteine in a context of neighbouring cysteines [5,38], the
corresponding CD20 and CD23 double mutations (C111A/
C220A for CD20 and C17A/C18A for CD23) were also analyzed.
The predicted topology of CD20 led us to build only the C111A/
C220A CD20 double mutant [35] (Figure 5).
In order to unambiguously annotate CD20 and CD23 as novel
palmitoylated proteins, transfected HEK-293T cells were meta-
bolically labeled with 17-ODYA for palmitoylation analysis
(Figure 6). This orthogonal labeling approach uses metabolic
labeling to attach a fatty acid analogue in native cells, providing an
additional validation of protein palmitoylation. Flotillin-1, a well-
established palmitoylated protein [39], was used as a positive
control. After labeling with 17-ODYA for 6 hours, cell mem-
branes were mixed with rhodamine-azide, TCEP, TBTA, and
copper sulphate under standard click chemistry conditions.
Samples were then separated by SDS-PAGE and analyzed using
a fluorescent scanner to detect 17-ODYA labeled proteins. For
each transfected protein, a hydroxylamine-sensitive fluorescent
band appeared in the transfected samples, indicative of protein
palmitoylation (Figure 6, left panels). The identity of the
fluorescent species was finally checked by western blot using an
Figure 4. Functional distribution of the candidate palmitoy-
lated proteins. The 93 proteins meeting the determined criteria for
being candidates (including known palmitoylated proteins, but
depleted from MHC molecules) were classified according to the
biological processes they are associated with, as described in the
Human Protein Reference Database. The ‘‘transport’’ category has been
further manually subdivided in ‘‘molecular transport’’ and ‘‘vesicular
transport’’ categories.
doi:10.1371/journal.pone.0037187.g004
Table 1. List of the peptides allowing the identification of
CD20 and CD23.
protein peptides position length
CD20 MESLNFIR (oxidized form) 149–156 8
MESLNFIR (dioxidized form) 149–156 8
SNIVLLSAEEK 225–235 11
SNIVLLSAEEKK 225–236 12
EEVVGLTETSSQPK 244–257 14
CD23 MEEGQYSEIEELPR 1–14 14
MEEGQYSEIEELPR (oxidized form) 1–14 14
SQSTQISQELEELR 83–96 14
SQSTQISQELEELRAEQQR 83–101 19
SQELNERNEASDLLER 125–140 16
NEASDLLER 132–140 9
YACDDMEGQLVSIHSPEEQDFLTK 189–212 24
GEFIWVDGSHVDYSNWAPGEPTSR 230–253 24
SQGEDCVMMR 254–263 10
SQGEDCVMMR (oxidized form) 254–263 10
doi:10.1371/journal.pone.0037187.t001
Figure 5. Schematic representation of CD20 and CD23.
Cysteines that are potential sites of palmitoylation are indicated, as
well as N and C termini. For the sake of simplicity, CD23 is depicted as a
monomer, although CD23 molecules are assembled in trimers in the
membrane [36]. The CD20 scheme is adapted with permission from
Ernst et al. [35]. Copyright (2005) American Chemical Society.
doi:10.1371/journal.pone.0037187.g005
CD20 and CD23 Are Novel Palmitoylated Proteins
PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e37187anti-His antibody, demonstrating alignment between unique
fluorescent 17-ODYA labeled bands and the (His)6-tagged species
(Figure 6, upper right panel). For all three proteins, one band only
was detected at the expected size for the complete tagged protein,
i.e. 51 kDa for flotillin-1, 37 kDa for CD20 and 43 kDa for CD23.
Based on these results, we conclude that CD20 and CD23, like
flotillin-1, are valid palmitoylated proteins measured by two
distinct palmitoylation detection schemes.
Mutational analysis also demonstrated that the C81A and
C111A mutants of CD20, but not the C220A mutant, incorpo-
rated equivalent amounts of 17-ODYA, relative to their expression
levels. The double mutant C111A/C220A completely eliminated
17-ODYA incorporation. Accordingly, CD20 is palmitoylated on
its intracytoplasmic cysteines Cys
111 and/or Cys
220. Single
mutants (C17A, C18A) of CD23 did not reduce the incorporation
of 17-ODYA, but the double mutant (C17A/C18A) completely
abrogated the observed labeling. Therefore, CD23 is palmitoy-
lated on either Cys
17 and/or Cys
18.
Discussion
In order to identify novel palmitoylated proteins in human B
lymphocytes, we used the ABE method [10] followed by a semi-
quantitative mass spectrometry analysis. The analysis of three
independent purifications allowed us to identify 493 proteins from
human B lymphoid cells, among which 53 were known
palmitoylated proteins. These included flotillins-1 and -2, vesicular
trafficking proteins, Ras-family GTPases, G-a subunits, kinases
and receptors, similarly to previous proteomic studies
[9,12,14,15,31]. Candidate palmitoylated proteins were identified
by semi-quantitative analysis using spectral counting approaches
[22] and comparison between samples prepared with or without
hydroxylamine treatment. The calculation of a spectral index [32]
led to the identification of 95 candidate palmitoylated proteins.
Given the overlap with previous efforts to profile palmitoylated
proteins in immune cells, we focused our interest on two proteins
involved in the immune response, CD20 and CD23, which were
both identified unambiguously as candidate palmitoylated proteins
in the present study. Interestingly, CD20 and CD23 are both
effective or promising targets for immunotherapy of haematolog-
ical malignancies, autoimmune diseases or allergy disorders
[26–29]. CD20 expression is restricted to pre-B and mature B
cells and regulates B cell activation and proliferation [40]. CD23,
also known as the low affinity receptor for immunoglobulin E, is a
transmembrane receptor expressed by various haematopoietic and
epithelial cells that participates in tuning the immune response by
regulating IgE production [41,42].
CD20 and CD23 palmitoylation was validated by heterologous
expression and metabolic labeling with the palmitate analog 17-
ODYA. CD20 and CD23 palmitoylation sites were also assessed
by systematic mutational analysis of intracytoplasmic or mem-
brane-embedded cysteines [5,37]. Although the single mutations
had no or only a limited effect on the protein palmitoylation, both
double mutations C111A/C220A (in CD20) and C17A/C18A (in
CD23) completely prevented this modification. This implies that
the palmitoylation site in CD20 or in CD23 actually resides in the
pairs of cysteines tested. It has been previously observed that single
mutants in neighbouring cysteines could be palmitoylated because
of aberrant modification of the remaining cysteines [5,38]. CD23
is clearly in this configuration of vicinal cysteines. Concerning
CD20, Cys
111 belongs to the intracellular loop between the second
and the third transmembrane domains, while Cys
220 is located in
the C-terminal tail. Despite their distance in the primary sequence,
they could nevertheless be in close proximity in the folded protein
Figure 6. The immune regulators CD20 and CD23 are novel palmitoylated proteins. HEK293T cells were transfected with plasmids
encoding His-tagged versions of flotillin-1, CD20, CD23 and Cys-to-Ala mutants of CD20 and CD23, and metabolically labeled with 17-ODYA. Cell
membranes were then subjected to click chemistry prior to separation of proteins by SDS-PAGE on a 10% acrylamide gel. Proteins were treated
(lower panels) or not (upper panels) with hydroxylamine before gel loading. Left panels: Scans of the fluorescent proteins. Right panels:
Immunodetection of the exogenous proteins with an anti-His antibody. Arrowheads indicate the position of overexpressed proteins. The figure is a
composite of two gels, as shown by a thick line. Lanes separated by a thin line were not originally contiguous in the gel, but were placed next to each
other in the figure for the sake of clarity. Gels and blots were cropped around the region of interest.
doi:10.1371/journal.pone.0037187.g006
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ments. Our observation that the C220A mutation was more
effective in reducing CD20 palmitoylation than did the C111A
one, indicative of Cys
220 modification, was corroborated by
previously published data. Indeed, the presence of post-transla-
tional modifications in the C-terminal region, such as phosphor-
ylation or acylation, had been proposed, as the observed molecular
weight of a CD20 C-terminal fragment resulting from protease
digestion of intact cells was found to significantly exceed its
expected size (21 kDa instead of 14; [34]). Besides, Cys
111 is the
only CD20 cysteine that is unique to humans and not conserved in
the mouse CD20 sequence [35], suggesting that palmitoylation of
this residue is unlikely to be essential for CD20 function.
Protein palmitoylation is a key regulatory mechanism for
numerous cellular processes that include membrane targeting,
segregation to membrane microdomains (i.e. lipid rafts), protein
stability, protein-protein interactions or cellular signaling [2,4–6].
Because CD20 and CD23 are both associated to cellular signaling
cascades and display multiple interactions with immune actors such
as the B cell receptor or the complement receptor CD21 [41,43–
46], their respective palmitoylation might be one of the switches
involved inthe tuningof CD20 or CD23 immuneactivityandinthe
cell response to anti-CD20 or anti-CD23 immunotherapy.
In conclusion, our analysis of the B lymphocyte palmitoyl-
proteome led to the selection and validation of the two immune
regulators CD20 and CD23 as B cell novel palmitoylated proteins.
These results open the way to future studies aiming at deciphering
the role of CD20 and CD23 palmitoylation in immune activation
and in cellular responses to B cell directed immuno-, radioimuno-
or chemoimmunotherapies.
Materials and Methods
Chemicals and reagents
Except when mentioned, chemicals were from Sigma-Aldrich.
Latrunculin B was purchased from Calbiochem. Complete,
EDTA-free, protease inhibitor cocktail and the Fugene HD
transfection reagent were from Roche. Hydroxylamine was
obtained from Alfa Aesar. EZ-Link biotin-HPDP was from
Thermo Scientific. 17-octadecynoic acid (17-ODYA) was obtained
from Cayman. The Colloidal Blue solution (Biosafe) and the BCA
assay were from BioRad. The modified trypsin (sequencing grade)
was purchased from Promega. Formic acid was obtained from
Aristar.
RPMI-GlutamaxI, penicillin-steptomycin-glutamine, and Dy-
nabeads M-280 streptavidin were obtained from Invitrogen. FBS
was from Invitrogen or Gemini. DMEM (High Glucose) and D-
PBS were purchased from Mediatech.
Palmitoylated protein purification from B lymphoblasts
A human Epstein-Barr virus-transformed B lymphoid cell line
was established in the lab from a donor whose parents had given
written informed consent for the establishment and storage of the
cell line, according to the protocols approved by the ethics review
board of the Toulouse Hospital. Research was performed in
compliance with the Declaration of Helsinki. Cells were grown in
RPMI-GlutaMaxI containing 10% FBS.
Palmitoylated proteins were purified from 200610
6 B cells
according to Wan et al. [47], except that Tris buffer was replaced
by Hepes. As preliminary experiments had demonstrated the very
high abundance of actin in our samples, that hampered
identification of other proteins, we also added a cell incubation
step in the presence of 400 mM latrunculin B in complete culture
medium for 30 minutes at 37uC prior to harvesting, in order to
deplete the sample from polymerized actin [48]. Cells were then
pelleted by centrifugation, resuspended at 50610
6 cells/mL (in
50 mM Hepes, pH 7.4, 150 mM NaCl, 5 mM EDTA, pH 8.0,
0.1% Triton X-100, protease inhibitors), and finally broken by
4 cycles of freezing/thawing before sonication. Total membranes
were recovered by high-speed centrifugation (100 0006g, 1 h,
4uC) and resolubilized in 50 mM Hepes, pH 7.4, 150 mM NaCl,
5 mM EDTA, pH 8.0, 1.7% Triton X-100, 10 mM N-ethylma-
leimide (NEM), protease inhibitors. Then, proteins were extracted
by methanol-chloroform precipitation. Resolubilized proteins were
incubated successively with NEM for blockade of free thiols, and
with hydroxylamine (HA+ sample) to release the thioester-linked
palmitate and restore the modified cysteines to thiols. Formerly
thioester-containing (mainly palmitoylated) proteins were biotiny-
lated using a thiol-reactive biotinylation reagent (EZ-Link biotin-
HPDP) and finally captured on streptavidin-coated magnetic
beads (Dynabeads M-280 streptavidin). Specifically bound pro-
teins were eluted by b-mercaptoethanol reduction of the protein-
biotin disulfide linkage. An essential control of non-specific
biotinylation and binding to the streptavidin matrix consisted in
replacing hydroxylamine by 50 mM Hepes, pH 7.4, in half of the
NEM-treated sample (HA2 sample).
Palmitoylation assays
HEK293T cells were cultured in DMEM (High Glucose)
supplemented with 10% FBS and 1% penicillin-steptomycin-
glutamine. Cells were transiently transfected using purified
plasmid DNA and Fugene HD transfection reagent. Twelve hours
after transfection, cells were labeled with 20 mM 17-ODYA for
8 hours, washed twice with D-PBS, and then harvested and frozen
at 280uC. Cell pellets were later sonicated in D-PBS and
separated into soluble and insoluble fractions by ultracentrifuga-
tion for 45 minutes at 100 0006 g. The insoluble pellet was
resuspended by sonication in D-PBS, and then quantified using
the BCA protein assay using a microplate reader. Cell lysates were
normalized to 1 mg/mL. To 100 mL of each lysate, click
chemistry reagents were added at room temperature to yield a
final concentration of 20 mM rhodamine-azide, 1 mM Tris(2-
carboxyethyl)phosphine (TCEP), 100 mM Tris[(1-benzyl-1H-
1,2,3-triazol-4-yl)methyl]amine (TBTA), and 1 mM CuSO4 in
PBS. After 1 hour, half of the sample (50 mL) was transferred to a
fresh tube and mixed with 1 M hydroxylamine and boiled for
5 minutes. All samples were mixed with 46SDS sample loading
buffer and 2/3 (33 mg) of the sample was loaded on a 10% SDS-
PAGE gel, separated over 850 volt-hours, and analyzed using a
Hitachi FMBIO-II flatbed fluorescence scanner. Gels were then
transferred to nitrocellulose (100 volt-hours), blocked with 5%
non-fat dry milk in Tris-buffered saline Tween-20 buffer (TBST),
incubated overnight in 2% bovine serum albumin with 1:2000
mouse anti-His (C-term) (Invitrogen) in TBST, washed, and
incubated with 1:10 000 goat anti-mouse IRDye 800CW (LiCOR)
for 1 hour. After washing, the membrane was imaged using an
Odyssey Imager (LiCOR).
SDS-PAGE analyses
ABE purified proteins were separated on SDS-polyacrylamide
gels (4–12%, NuPage, Invitrogen). They were revealed either by
silver staining for analytical purpose or by colloidal blue staining
for mass spectrometry analysis.
Cloning and DNA manipulation
cDNAs encoding CD23a and flotillin-1 tagged with a C-
terminal V5-His(6) sequence were purchased as pDEST51-based
plasmids (respectively OCAAo5051D0795 and
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The CD20 cDNA was amplified by PCR from human B cells
cDNA, with the following primers: 59-ATTGGATCCGCCGC-
CATGACAACACCCAGAAATTC-39 and 59-GCGCTCGA-
GAGGAGAGCTGTCATTTTC-39, and cloned into
pcDNA3.1/myc-His (Invitrogen) at the BamHI and XhoI sites to
generate pcDNA3.1-CD20-myc-His.
Cys-to-Ala point mutations were generated by site-directed
mutagenesis (QuickChange Lightning Site-Directed Mutagenesis
kit, Agilent Technologies), according to the manufacturer instruc-
tions. The CD20 insert was first transferred into the pUC18 vector
for directed mutagenesis, and then the mutated insert was
returned back to the pcDNA3.1/myc-His vector, using NdeI and
XbaI sites at both steps. The CD23 insert was transferred by use of
the Gateway technology (Invitrogen) into a pENTR221 vector,
subjected to directed mutagenesis and returned to the pDEST51
Gateway vector. The primers used for generating the mutations
were the following: 59-GGATCTATGCACCCATCGCTGT-
GACTGTGTGGTACC-39 and 59-GGTACCACACAGTCA-
CAGCGATGGGTGCATAGATCC-39 for CD20 C81A; 59-CG-
GAGAAAAACTCCAGGAAGGCTTTGGTCAAAGGAAAAA-
TG-39 and 59-CATTTTTCCTTTGACCAAAGCCTTCCTG-
GAGTTTTTCTCCG-39 for CD20 C111A; 59-GAGAATGA-
ATGGAAAAGAACGGCCTCCAGACCCAAATCTAAC - 39
and 59-GTTAGATTTGGGTCTGGAGGCCGTTCTTTTCC-
ATTCATTCTC-39 for CD20 C220A; 59-TCCCAGGAGG-
CGGGCTTGCAGGCGTGGG-39 and 59-CCCACGCCTG-
CAAGCCCGCCTCCTGGGA-39 for CD23 C17A; 59-CCAG-
GAGGCGGTGTGCCAGGCGTGGGACT-39 and 59-AGTCC-
CACGCCTGGCACACCGCCTCCTGG-39 for CD23 C18A;
59-GCTTCCCAGGAGGCGGGCTGCCAGGCGTGGGACT -
C-39 and 59-GAGTCCCACGCCTGGCAGCCCGCCTCCT-
GGGAAGC-39 for CD23 C17A/C18A.
All constructs were checked by DNA sequencing (Cogenics).
Mass spectrometry
Protein digestion. Protein bands covering the entire migra-
tion zone of the SDS-polyacrylamide gel were systematically and
manually excised and washed several times by incubation in
25 mM NH4HCO3 (solution A) for 15 min followed by 50% (v/v)
acetonitrile containing 25 mM NH4HCO3 (solution B) for 15 min.
Gel pieces were dehydrated with 100% acetonitrile and then
incubated with 7% H2O2 for 15 min before being washed again
with solutions A and B as previously. 0.15 mg of modified trypsin
in solution A was added to the dehydrated gel bands for an
overnight incubation at 37uC. Peptides were then extracted from
gel pieces in three 15 min sequential extraction steps in 30 mLo f
50% acetonitrile, 30 mL of 5% formic acid and finally 30 mLo f
100% acetonitrile. The pooled supernatants were finally dried
under vacuum.
Nano-LC-MS/MS analysis. The dried extracted peptides
were resuspended in 4% acetonitrile and 0.5% trifluoroacetic acid
and analyzed by online nanoLC-MS/MS (Ultimate 3000 and
LTQ-Orbitrap, Thermo Fischer Scientific). The nanoLC method
consisted in a 40 min gradient ranging from 5% to 55%
acetronitrile in 0.1% formic acid at a flow rate of 300 nL/min.
Peptides were sampled on a 300 mm65 mm PepMap C18
precolumn and separated on a 75 mm6150 mm C18 column
(Gemini C18, Phenomenex). MS and MS/MS data were acquired
using Xcalibur (Thermo Fischer Scientific) and processed auto-
matically using Mascot Daemon software (version 2.3, Matrix
Science).
Database searching. Consecutive searches against a home-
made polypeptide sequence database were performed for each
sample using Mascot 2.3. The search database consisted in the
concatenation of the SwissProt-Trembl database (release 2010_07,
Homo sapiens taxonomy, 92 013 entries), the corresponding reverse
sequences and classical contaminants (trypsin from pig, proteins
from bovine serum, etc., 258 entries). ESI-TRAP was chosen as
the instrument, trypsin as the enzyme and 2 missed cleavages
allowed. Precursor and fragment mass error tolerance were set
respectively at 10 ppm and 0.6 Da. Peptide modifications allowed
during the search were: acetyl (N-ter), dioxidation (M), oxidation
(M) and trioxidation (C). Proteins identified with a minimum of 1
peptide and with a score higher than the identity threshold (p-
value,0.05) were automatically validated using IRMa [49].
Results were downloaded into an MSI database displaying a false
positive rate of 0.90% [50]. This database was then treated by a
homemade software (hEIDI) for the compilation, filtering,
grouping and comparison of the proteins. The filter rejected
proteins identified by one peptide only. Finally, identifications of
contaminant sequences (trypsin, keratins and non-human proteins)
were removed from the protein list. The MS results are available
in the PRIDE database (http://www.ebi.ac.uk/pride) under
accession number 20197 [51].
Semi-quantitative analysis. For each identified protein, its
spectral count value was determined and normalized to the total
number of assigned spectra in the considered sample. Normalized
values were considered for evaluation of the relative protein
abundance in each sample using the label free spectral counting
method [22]. A spectral index (SpI) was then determined for each
protein as indicated in Fu et al. [32] to allow comparison between
HA- and HA+ samples and help determination of palmitoylated
protein candidates.
Supporting Information
Table S1 List of identified proteins. Identification results
from all samples were merged and proteins were grouped to
respect the principle of parsimony. Only proteins identified by at
least two peptides were retained. Proteins that have been
previously established as palmitoylated (‘‘Established’’) or identi-
fied as candidates in previous proteomic screens (‘‘Proteomics’’)
are indicated along with the corresponding reference. The list of
references is below the table. The spectral index has been
calculated as described in Fu et al. (J. Proteome Re.,
2008;7(3):845–854). NA (not applicable): a spectral index is
calculated only for proteins that are present in both HA+ and
HA2 samples. For the proteins that are not identified in one
category of samples (HA+ or HA2), the averaged normalized
spectral count of this sample is considered as equal to 0. Sc:
spectral count; nsc: normalized spectral count (spectral count of a
protein divided by the total number of assigned spectra in the
corresponding sample). Exp1 to 3 correspond to the three
biological replicates.
(XLS)
Table S2 Detail of the distribution of the proteins
meeting selection criteria. HA+ only : proteins identified in
HA+ samples exclusively. Common proteins: proteins identified in
both HA+ and HA2 samples. P-value: p-value related to the
spectral index analysis.
(XLS)
Table S3 Candidate palmitoylated proteins. Proteins
meeting our criteria of potential palmitoylation are listed. They
include well-established palmitoylated proteins («Established»),
proteins previously identified as candidates in proteomic screens
(«Proteomics»), and novel candidates («Novel»). They are
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indicated in the Human Protein Reference Database and
manually reviewed. NA (not applicable): no SpI was calculated
for proteins identified exclusively in HA+ samples.
(XLS)
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